Timothy Clay

2.0k total citations
84 papers, 1.2k citations indexed

About

Timothy Clay is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Immunology. According to data from OpenAlex, Timothy Clay has authored 84 papers receiving a total of 1.2k indexed citations (citations by other indexed papers that have themselves been cited), including 54 papers in Oncology, 21 papers in Pulmonary and Respiratory Medicine and 20 papers in Immunology. Recurrent topics in Timothy Clay's work include Cancer Immunotherapy and Biomarkers (20 papers), Immunotherapy and Immune Responses (13 papers) and CAR-T cell therapy research (10 papers). Timothy Clay is often cited by papers focused on Cancer Immunotherapy and Biomarkers (20 papers), Immunotherapy and Immune Responses (13 papers) and CAR-T cell therapy research (10 papers). Timothy Clay collaborates with scholars based in Australia, United States and United Kingdom. Timothy Clay's co-authors include H. Kim Lyerly, Michael A. Morse, Takuya Osada, Amy Hobeika, Robert U. Newton, Nicolas H. Hart, Herbert I. Hurwitz, Gabriel T. Chong, Timothy Hong and I K Dev and has published in prestigious journals such as Circulation, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

Timothy Clay

70 papers receiving 1.2k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Timothy Clay Australia	18	637	464	309	177	97	84	1.2k
Jenny Wu United States	15	623 1.0×	582 1.3×	198 0.6×	166 0.9×	59 0.6×	38	1.4k
Teresa Rodríguez Spain	19	546 0.9×	253 0.5×	146 0.5×	131 0.7×	119 1.2×	34	973
Jacqueline Jones United States	14	481 0.8×	228 0.5×	320 1.0×	186 1.1×	141 1.5×	28	1.2k
Shane White Australia	17	465 0.7×	223 0.5×	233 0.8×	251 1.4×	56 0.6×	46	835
Alexander Siebenhüner Switzerland	13	574 0.9×	210 0.5×	159 0.5×	198 1.1×	135 1.4×	44	1.1k
Zhen Ni Zhou United States	13	398 0.6×	490 1.1×	172 0.6×	84 0.5×	98 1.0×	27	996
Andreas Trojan Switzerland	22	741 1.2×	567 1.2×	339 1.1×	295 1.7×	151 1.6×	64	1.8k
Jinke Li China	13	537 0.8×	401 0.9×	665 2.2×	405 2.3×	391 4.0×	42	1.6k
Elísabeth Pérez-Ruiz Spain	20	1.0k 1.6×	600 1.3×	574 1.9×	339 1.9×	302 3.1×	80	1.9k
Amy M. Lehman United States	19	608 1.0×	385 0.8×	514 1.7×	111 0.6×	90 0.9×	34	1.5k

Countries citing papers authored by Timothy Clay

Since Specialization

Citations

This map shows the geographic impact of Timothy Clay's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Timothy Clay with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Timothy Clay more than expected).

Fields of papers citing papers by Timothy Clay

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Timothy Clay. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Timothy Clay. The network helps show where Timothy Clay may publish in the future.

Co-authorship network of co-authors of Timothy Clay

This figure shows the co-authorship network connecting the top 25 collaborators of Timothy Clay. A scholar is included among the top collaborators of Timothy Clay based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Timothy Clay. Timothy Clay is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Faltys, Martin, Marliese Alexander, Sagun Parakh, et al.. (2025). Second-line treatment strategies and clinical outcomes after progression on chemoimmunotherapy in extensive-stage small-cell lung cancer. Lung Cancer. 209. 108786–108786.

Majem, Margarita, Enric Carcereny, Bernard Doger, et al.. (2025). Eftilagimod Alpha Plus Pembrolizumab in First-Line Metastatic Non–Small Cell Lung Cancer: Results From a PD-L1–Unselected Population in the TACTI-002 Study.

Taaffe, Dennis R., Alice Avancini, Sara Pilotto, et al.. (2025). Effects of exercise on inflammation in female survivors of nonmetastatic breast cancer: a systematic review and meta-analysis. JNCI Journal of the National Cancer Institute. 117(10). 1984–1998. 8 indexed citations

Taaffe, Dennis R., Timothy Clay, Mauro De Santi, et al.. (2025). Effects of Resistance versus High-Intensity Interval Training on Myokines and Cancer Cell Suppression in Breast Cancer Survivors: A Randomized Trial. Medicine & Science in Sports & Exercise. 58(1). 1–9.

Alexander, Marliese, Sagun Parakh, Paul Mitchell, et al.. (2024). Lurbinectedin in small cell lung cancer: real‐world experience of a multicentre national early access programme. Australasian Journal of Paramedicine. 54(7). 1087–1096. 5 indexed citations

Taaffe, Dennis R., et al.. (2024). Effects of resistance training vs high intensity interval training on body composition, muscle strength, cardiorespiratory fitness, and quality of life in survivors of breast cancer: a randomized trial. Breast Cancer Research and Treatment. 210(2). 261–270. 7 indexed citations

Alexander, Michael J., Michael Faltys, Lydia Warburton, et al.. (2023). 538P First-line chemoimmunotherapy for metastatic thymic carcinoma. Annals of Oncology. 34. S1679–S1680.

Carcereny, Enric, Enriqueta Felip, Margarita Majem, et al.. (2023). 1312MO Combining the antigen-presenting cell activator eftilagimod alpha (soluble LAG-3) and pembrolizumab: Overall survival data from the first line non-small cell lung carcinoma (NSCLC) cohort of TACTI-002 (phase II). Annals of Oncology. 34. S754–S754. 3 indexed citations

Krebs, Matthew, M. Majem Tarruella, Martin Förster, et al.. (2022). 11P Results of a phase II study investigating eftilagimod alpha (soluble LAG-3 protein) and pembrolizumab in second-line PD-1/PD-L1 refractory metastatic non-small cell lung carcinoma pts. Annals of Oncology. 33. S33–S33. 2 indexed citations

10.

Majem, Margarita, Enriqueta Felip, Bernard Doger, et al.. (2020). 1266P Initial results from a phase II study (TACTI-002) of eftilagimod alpha (soluble LAG-3 protein) and pembrolizumab in patients with PD-L1 unselected first-line metastatic non-small cell lung carcinoma. Annals of Oncology. 31. S818–S818. 4 indexed citations

11.

Rudin, Charles M., Hardev Pandha, Sumati Gupta, et al.. (2018). Phase Ib KEYNOTE-200: A study of an intravenously delivered oncolytic virus, coxsackievirus A21 in combination with pembrolizumab in advanced NSCLC and bladder cancer patients. Annals of Oncology. 29. viii732–viii732. 15 indexed citations

12.

Saudemont, Aurore, Laurent Jespers, & Timothy Clay. (2018). Current Status of Gene Engineering Cell Therapeutics. Frontiers in Immunology. 9. 153–153. 29 indexed citations

13.

Clay, Timothy & Samantha Bowyer. (2018). Dabrafenib and trametinib treatment-associated fevers in metastatic melanoma causing extreme elevation in procalcitonin in the absence of infection. Anti-Cancer Drugs. 29(8). 802–805. 6 indexed citations

14.

Osada, Takuya, William T. Barry, Xiao Yang, et al.. (2012). Characterization of an Oxaliplatin Sensitivity Predictor in a Preclinical Murine Model of Colorectal Cancer. Molecular Cancer Therapeutics. 11(7). 1500–1509. 31 indexed citations

15.

Morse, Michael A., Robert Chapman, John D. Powderly, et al.. (2011). Phase I Study Utilizing a Novel Antigen-Presenting Cell–Targeted Vaccine with Toll-like Receptor Stimulation to Induce Immunity to Self-antigens in Cancer Patients. Clinical Cancer Research. 17(14). 4844–4853. 112 indexed citations

16.

Einarsdóttir, Kristjana, et al.. (2009). Effect of a Single ‘Megadose’ Intramuscular Vitamin D (600,000 IU) Injection on Vitamin D Concentrations and Bone Mineral Density Following Biliopancreatic Diversion Surgery. Obesity Surgery. 20(6). 732–737. 31 indexed citations

17.

Aird, Katherine M., Aris Baras, Jun-Ping Wei, et al.. (2008). Trastuzumab signaling in ErbB2-overexpressing inflammatory breast cancer correlates with X-linked inhibitor of apoptosis protein expression. Molecular Cancer Therapeutics. 7(1). 38–47. 54 indexed citations

18.

Hobeika, Amy, Takuya Osada, Delila Serra, et al.. (2008). Detailed analysis of cytomegalovirus (CMV)-specific T cells expanded for adoptive immunotherapy of CMV infection following allogeneic stem cell transplantation for malignant disease. Cytotherapy. 10(3). 289–302. 7 indexed citations

19.

Wei, Jun-Ping, Takuya Osada, Xiao Yang, et al.. (2007). Adenovirus-human HER2 vaccine inhibits breast cancer growth and vaccine induced antibodies (VIA) are efficacious against Herceptin-refractory human breast cancer (48.32). The Journal of Immunology. 178(1_Supplement). S81–S81. 1 indexed citations

20.

Osada, Takuya, Timothy Clay, Amy Hobeika, H. Kim Lyerly, & Michael A. Morse. (2005). NK cell activation by dendritic cell vaccine: a mechanism of action for clinical activity. Cancer Immunology Immunotherapy. 55(9). 1122–1131. 55 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact